An editor and writer specialising in pharma, biotech and healthcare, Dominic Tyer is pharmaphorum's creative and editorial director and interim managing editor.
Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic.
Europe’s medicines regulator is expecting higher-than-anticipated staff departures as a result of its Brexit-induced move from London to Amsterdam next year.
The rankings of the top pharmaceutical companies in the world in 2017 presented a mixed picture, with stability for some of the 25 largest firms as others saw their value fall.
European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim, Sams
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
